114 related articles for article (PubMed ID: 10687147)
21. Overview of clinical trials employing antibody-targeted superantigens.
Persson B; Persson R; Weiner LM; Alpaugh RK
Adv Drug Deliv Rev; 1998 Apr; 31(1-2):143-152. PubMed ID: 10837622
[TBL] [Abstract][Full Text] [Related]
22. Targeted superantigens for immunotherapy of haematopoietic tumours.
Tötterman TH; Gidlöf C; Ragnarsson L; Högbom E; Lindeberg M; von der Lehr N; Einarsson A; Soegaard M; Kristensson K; Kalland T; Dohlsten M
Vox Sang; 1998; 74 Suppl 2():483-7. PubMed ID: 9704486
[TBL] [Abstract][Full Text] [Related]
23. Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy.
Erlandsson E; Andersson K; Cavallin A; Nilsson A; Larsson-Lorek U; Niss U; Sjöberg A; Wallén-Ohman M; Antonsson P; Walse B; Forsberg G
J Mol Biol; 2003 Nov; 333(5):893-905. PubMed ID: 14583188
[TBL] [Abstract][Full Text] [Related]
24. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects.
Kroesen BJ; Janssen RA; Buter J; Nieken J; Sleijfer DT; Mulder NH; De Leij L
J Hematother; 1995 Oct; 4(5):409-14. PubMed ID: 8581377
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
[TBL] [Abstract][Full Text] [Related]
26. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
27. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
Takemura S; Kudo T; Asano R; Suzuki M; Tsumoto K; Sakurai N; Katayose Y; Kodama H; Yoshida H; Ebara S; Saeki H; Imai K; Matsuno S; Kumagai I
Cancer Immunol Immunother; 2002 Mar; 51(1):33-44. PubMed ID: 11845258
[TBL] [Abstract][Full Text] [Related]
28. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial.
Gulec SA; Cohen SJ; Pennington KL; Zuckier LS; Hauke RJ; Horne H; Wegener WA; Teoh N; Gold DV; Sharkey RM; Goldenberg DM
Clin Cancer Res; 2011 Jun; 17(12):4091-100. PubMed ID: 21527562
[TBL] [Abstract][Full Text] [Related]
29. Genetically engineered superantigens as tolerable antitumor agents.
Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck NG; Litton MJ; Kalland T; Dohlsten M
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2489-94. PubMed ID: 9122222
[TBL] [Abstract][Full Text] [Related]
30. Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243).
Sessa C; Zucchetti M; Ghielmini M; Bauer J; D'Incalci M; de Jong J; Naegele H; Rossi S; Pacciarini MA; Domenigoni L; Cavalli F
Cancer Chemother Pharmacol; 1999; 44(5):403-10. PubMed ID: 10501914
[TBL] [Abstract][Full Text] [Related]
31. Effects of a superantigen-antibody recombinant fusion protein (r-C242 Fab-SEA) on toxicological responses in the anaesthetised rabbit.
Ilbäck NG; Gunnarsson K; Persson R; Lindh U; Stålhandske T
Toxicology; 2003 Mar; 185(1-2):161-74. PubMed ID: 12505454
[TBL] [Abstract][Full Text] [Related]
32. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibodies and superantigens: a novel therapeutic approach.
Kalland T; Dohlsten M; Lind P; Sundstedt A; Abrahmsén L; Hedlund G; Björk P; Lando PA; Björklund M
Med Oncol Tumor Pharmacother; 1993; 10(1-2):37-47. PubMed ID: 8258993
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.
Saif MW; Knost JA; Chiorean EG; Kambhampati SR; Yu D; Pytowski B; Qin A; Kauh JS; O'Neil BH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):815-24. PubMed ID: 27566701
[TBL] [Abstract][Full Text] [Related]
35. Developing a manufacturing process and analyses for a recombinant protein drug.
Florin-Robertsson E
Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):149-50. PubMed ID: 15119032
[No Abstract] [Full Text] [Related]
36. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
37. Preparation and in-vitro bioactivity of a novel superantigen conjugate targeting bladder carcinoma.
Zhen G; Cong-hui H; Lin H; Jian-jun Y; Wen-hao T; Gao-jun T
J Pharm Pharmacol; 2009 Jul; 61(7):869-75. PubMed ID: 19589228
[TBL] [Abstract][Full Text] [Related]
38. In vitro biological activities of transmembrane superantigen staphylococcal enterotoxin A fusion protein.
Ma W; Yu H; Wang Q; Bao J; Yan J; Jin H
Cancer Immunol Immunother; 2004 Feb; 53(2):118-24. PubMed ID: 14574492
[TBL] [Abstract][Full Text] [Related]
39. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
40. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
